The incorporation of thymidine (thymine deoxyriboside) into deoxyribonucleic acid (DNA) of proliferating cells has been studied in the past with various isotopic labels and biochemical techniques. Reichard and Estborn showed that thymidine-N15 was a specific precursor of DNA thymine in rats (1). Friedkin, Tilson, Roberts and Wood (2, 3) used thymidine-2-CI4 to show that this compound was incorporated into DNA thymidine of proliferating embryo and animal tissues with negligible partition of radioactivity into other components of DNA or into ribonucleic acid.
The incorporation of thymidine (thymine deoxyriboside) into deoxyribonucleic acid (DNA) of proliferating cells has been studied in the past with various isotopic labels and biochemical techniques. Reichard and Estborn showed that thymidine-N15 was a specific precursor of DNA thymine in rats (1) . Friedkin, Tilson, Roberts and Wood (2, 3) used thymidine-2-CI4 to show that this compound was incorporated into DNA thymidine of proliferating embryo and animal tissues with negligible partition of radioactivity into other components of DNA or into ribonucleic acid.
The recent synthesis of tritium-labeled thymidine by Taylor, Woods and Hughes (4) has made available thymidine labeled with a nonexchangeable long-lived, low energy beta emitter (0.018 Mev). Detection of this weak energy beta has been facilitated by the introduction of liquid scintillation spectrometers. Tritium-labeling of this DNA precursor has been further exploited in detecting newly formed DNA of single proliferating cells. The very low energy of the tritium /8 [a maximum range in tissue of only 7 IL; half of the betas travel less than 1 IA (5)] makes possible high-resolution autoradiograms of labeled cell nuclei. The water insolubility of DNA after cytological fixation is fortunate, since autoradiography carried out by usual stripping film technique requires aqueous solutions that remove soluble tritiated compounds.
Tritiated thymidine is being used in this laboratory to investigate cell turnover and dynamics of human and animal tissues studied both in vivo * Published in abstract form in Clinical Research, April, 1958. § Present address: Czerny-Krankenhaus fur Strahlenbehandlung der Universitat, Heidelberg, Germany. and in vitro by serial autoradiographic evaluation of labeled cell populations (6) (7) (8) (9) . In the course of these in vivo investigations it became important to assess the availability time of tritiated thymidine for incorporation into DNA following rapid intravenous injection. It is essential for serial study of proliferating cell populations that the H3-thymidine label be available for incorporation into new DNA for only a small part of the DNA synthesis time, and that afterward there be no further label availability. This short availability time of H3-thymidine then permits study of the various components of the generation cycles (preand postmitotic rests, mitosis and DNA synthesis) by serial study of the appearance of labeled mitotic figures, the appearance of labeled nondividing cells and the decrease of labeling upon subsequent successive mitoses. From these data a kinetic analysis should determine the flow rate between compartments and the time spent in each state (8, 9) .
The metabolic studies reported here indicate that the effective availability time for intravenously administered H3-thymidine is a matter of minutes. The metabolic fate of this tritium-labeled compound was examined by analyses of serial specimens of plasma, stool and urine as well as by evaluation of autoradiograms of tissues. These studies revealed that catabolism of some H3-thymidine to tritiated water (THO) as well as to nonvolatile tritiated compounds occurs. From the data to be presented here it appears that at least 50 per cent of injected H3-thymidine was retained in vivo and was presumably incorporated into new DNA of proliferating cells.
Recently Fink, Kline, Henderson and Fink (10), described a pathway of thymine degradation resulting in the formation of /3-aminoisobutyric acid (BAIBA). BAIBA excretion following H3-thymidine injection was studied in these patients, and tritiated BAIBA was identified in the urine. Brookhaven 9 months later, the patient was ambulatory and alert. He was well nourished and the vital signs were normal. Physical examination revealed residual left homonymous hemianopsia and left partial hemiplegia. All operative scars were well healed. The remainder of the physical examination was unremarkable. The hematocrit was 40 per cent and the leukocyte count was 4,000 per cu mm. The peripheral blood smear was normal and bone marrow aspirates revealed normal hematopoiesis. Urinalyses were normal as were determinations of blood urea nitrogen, uric acid and liver functions. Stools were guaiac negative. Chest X-rays were unremarkable and the electrocardiogram was normal.
After a two month hospital stay during which time he remained afebrile and unchanged clinically, the patient received an injection of H3-thymidine and subsequently returned to his home; he died 4 months later. Autopsy was not performed. In Table I are shown data relevant to the H3-thymidine injection in this patient.
METHODS
1. H3-thyrnidine. Thymine-6H3-deoxyriboside, molecular weight 242, was obtained1 in vials containing sterile 10 ml pyrogen-free aqueous solutions of 1 mc per ml. Specific activities varied initially from 0.208 c to 1.9 c per mmole. The compound was recrystallized with carrier thymidine and found free of impurities by paper chromatography.
2. H3-thymidine injectiont. After control plasma and urine specimens were obtained, a rapid injection of H3-thymidine was made into the tubing of an intravenous drip and flushed promptly with saline. Timed heparinized or oxalated blood specimens were obtained without stasis from the opposite arm at frequent intervals during the first hour, then less frequently as is described in the data. Urine and plasma specimens were collected under mineral oil to reduce tritiated water (THO) exchange with air water vapor and were promptly frozen and stored until further processing could be done.
3. Liquid scintillation counting. Tritium activity was determined using a liquid scintillation spectrometer.2 The liquid counting system consisted of the sample dissolved in absolute ethanol and 0.3 per cent 2-(4-biphenyl)-5-phenyl-3, 4-oxadiazole (PBD) in xylene. The efficiency of this system for aqueous H3 counting was 10 per cent as determined by counting known H3 standards prepared similarly. One sample counted 25 times showed a mean of 4,985 cpm with a standard error (11) of 42. Groups of samples were counted with known H3 standards and small corrections were made for slight changes in efficiency on different days. New counting vials 3 were used throughout and discarded after use.
4. THO determination (12) . Urine or plasma aliquots were rapidly pipetted into size-matched 60 X 15 mm (13) .
In calculating the maximum amount of H'-thymidine catabolized to THO following injection into the patient, the urine or plasma specimen with the highest THO activity was considered representative of THO activity distributed in total body water (TBW) at that time. TBW was estimated on the assumption that it is 52 per cent in normal men (14) and that weight loss with loss of subcutaneous fat would increase TBW. Estimates of TBW in the patients at the time of H3-thymidine injections are shown in Table I P X 103W = (total) dpm; dpm X 4.55 X 10" mc per dpm =mc (THO).
Daily plasma and urine THO activity was plotted on the log ordinate versus days, and the best resultant straight line was used to estimate the biological half-life of the THO.
5. Total H3 activity. Total H3 activity was estimated by combining 100 ,ul of plasma or urine with 3.4 ml ethanol in a conical centrifuge tube. After capping and mixing, the tube was centrifuged briefly to separate the protein solids and chromogens. Three ml of the ethanol extract containing H3 compounds soluble in the ethanol mixture was removed and added to 12 ml PBD-xylene in a counting vial for H3 counting. The activity obtained was corrected for the residual volume remaining in the centrifuge.tube and expressed therefore as cpm per 100 ,ul plasma or urine. There was no H' activity in the insoluble ethanol-washed precipitate. Determination of total H3 activity of a prepared mixture of H3-thymidine in water and H'-thymidine in plasma gave identical results. In another preliminary experiment, H'-thymidine was found to be readily dialyzable from plasma. Six separate determinations of total H3 activity on the same plasma had a mean of 3,460 cpm with a standard error of 20 cpm.
6. Nonvolatile H3 activity. Nonvolatile H3 activity represents the difference between total H' activity and THO activity of the same sample. Plasma nonvolatile H3 activity was estimated from curves of total H' activity and THO activity of the plasmas. In the case of urine specimens, nonvolatile H' activity was always obtained by subtracting THO activity from total H3 activity of each sample. Urine nonvolatile H3 activity in ,uc was calculated as follows: A = cpm per 100 ,l nonvolatile H3 activity. 100A = dpm per ml urine nonvolatile H3 activity. V = urine volume in ml. V X 100A x 4.55 x 10' = /Ac excreted.
7. Autoradiography. Autoradiograms of bone marrow and white cell concentrates of peripheral blood were prepared as previously described (7). 
RESULTS
Plasma H3 activity following H3-thymidine injection rose to a maximum within one minute after injection and then declined precipitously.
However, it should be pointed out that H3-thymidine was being lost simultaneously with mixing and maximal activity (5,800 cpm per ul) was found at one minute after injection. If uniform mixing had occurred without loss from the plasma the maximum would have been about 60,000 cpm. Hence about 90 per cent of the injected activity was lost from the blood in the first minute. In all instances studied (D.S. I and II, as well as W.S.), the curves of plasma total H3 activity, nonvolatile H3 activity and THO activity were very similar. In Figure 1 residual THO from previous injections was mad where appropriate in the calculations. Tritium water formed after H3-thymidine in jection thus reached a maximum and then gradu ally declined over the ensuing days. When dail THO activities of plasmas and urines after in jection were plotted on semilog paper, as show in Figure 5 , straight lines were obtained. Th curves as shown are uncorrected for previou residual THO in D.S. V but this does not affec the slope. The biological half-life of the TH( after injection, obtained from the slopes of th water curves shown in the figure, was from 7 t 12 days, compatible with the observed water bal ance. The absence of changes in slope or evider increase in THO concentration indicates that fur ther large increments of THO were not forme after the initial maximum from degradation c labeled DNA or other sources. If continuou degradation of small amounts of H3-DNA occur it is not detected.
Significant amounts of nonvolatile H3 activit were found in the urine only during the first 2 hours after H3-thymidine injection in these patients. In Figure 6 , urine nonvolatile H3 activity excretion in uc per ml is plotted as a function of time after injection. In Patient D.S. significant amounts of urine nonvolatile H3 activity were excreted only during the first six hours after H3-thymidine injection. In Patient W.S. excretion was detectable in his urine for almost the entire first day. The nonvolatile Hf3 activity excreted during the first day is shown in Table I , as nonvolatile H3 activity in microcuries and as per cent of the initial injection of H3-thymidine.
Urine collected for the first hour was desalted and chromatographed. Examination with ultraviolet light failed to show absorption spots characteristic of intact pyrimidines. BAIBA spots were eluted from two-dimensional chromatograms of these early urines and counted for H3 activity. The presence of H3-BAIBA was established and appeared to be the major component of urine nonvolatile Hf3 activity. Patient W.S. regularly excreted unlabeled BAIBA in his urine in abnormally large amounts in contrast to D.S. whose urines contained essentially normal amounts of BAIBA.
Stools were passed infrequently by these pale tients. However, three stools from Patient D.S.
passed.during the first two weeks after injection l-of H3-thymidine were found to have THO ac-1-tivity equal to body water on the day passed. y Attempts to find nonvolatile H3 activity in stools l after homogenation and extraction with ethanol, n butanol or water failed to reveal detectable -[S. 8.25 12- :THO THO activity equal to body water. No nonvolatile H3 activity was found. Data obtained following the injection of H3-thymidine in D.S. III through VI are shown in Table I . In view of the critical condition of the patient on these occasions, samples obtained of plasma and urine were inadequate to evaluate fully the changes which occurred in H3 metabolism. Approximately 60 per cent of the H3-thymidine was catabolized to THO and there was also an increased excretion of nonvolatile H3 activity under these conditions. It appeared that less H3-thymidine was incorporated into DNA and more was diverted into other metabolic pathways.
DISCUSSION
The present metabolic studies after H3-thymidine administration in human beings yielded results similar to those of H3-thymidine in mice as reported by Hughes and colleagues (18) . One hour following injection, about one-half of the administered tritiated thymidine is catabolized to THO, while the rest is presumably incorporated into DNA or converted to other compounds not identified.
These studies show that plasma is being cleared so rapidly in the first passage of the blood through the capillary bed that the entire amount injected is never uniformly mixed in plasma. At 1.5 min- (6) . Studies on the increasing average grain count of basophilic normoblasts confirm the rapid DNA synthesis and short availability time of the H3-thymidine for labeling, as is shown in Figure 7 . Other cell lineages behave similarly. Hence, from these radiobiochemical and autoradiographic studies, the labeling process is seen to be essentially complete by about 60 minutes and most of the incorporation has occurred in the first 10 to 15 minutes after injection. At completion of DNA synthesis, the H3 label is assumed to remain in those cells for their life span and to be diluted only by mitosis. Since the effective availability time of H3-thymidine for incorporation into DNA is a small fraction of the time for DNA synthesis, then the ratio of labeled cells to total cells of a cell type approximates the ratio of the time for DNA synthesis to generation time of that cell lineage.
Radiation effects from H3-thymidine were not seen clinically in these patients. Higher doses of H3-thymidine will produce evident damage. Problems relating to H3-thymidine dosimetry and radiation effects have been discussed by Johnson and Cronkite (19) and by Hughes and associates (20) elsewhere.
When H3-thymidine of increasing specific activities was injected, as shown in Table I , essentially similar curves of plasma clearance during the first hour were obtained; this suggests that H3-thymidine was handled as if it were a tracer. Even in a patient who received only 3 mc of H3-thymidine (21), the plasma clearance was identical with that resulting from 9 and 19 mc. Also, the per cent of THO catabolized from H3-thymidine in D.S. I, II and W.S. is seen to be independent of the amount of H3-thymidine administered and further supports the view that H3-thymidine behaves as a tracer.
There is a striking increase in THO formation and a concurrent rise in urine nonvolatile H3 activity excretion from H3-thymidine injection in D.S. III through VI. During these periods the patient was markedly cachetic and it might be postulated that total DNA synthesis was reduced either by a change in cell turnover rate or by a decrease in the DNA synthesizing cell mass. Bone marrow autoradiographs during these intervals showed the usual labeling. In any event, during these circumstances more THO was produced from the injected H3-thymidine. Accordingly, it appears that the fraction of thymidine not incorporated into DNA is degraded through the steps which produce THO and nonvolatile tritiated compounds. This concept is supported by the fact that reduction in the mass of DNA synthesizing tissues by whole body irradiation in rats and guinea pigs (22) results in catabolism of a larger proportion of injected H3-thymidine to THO and increased excretion of nonvolatile H3 activity.
In Patient W.S. considerably greater amounts of urine nonvolatile tritium activity were excreted during the first day after H3-thymidine injection than were excreted in D.S. I and II. The main component of this urine nonvolatile H3 activity was H3-BAIBA. Patient W.S. had been excreting approximately 500 ,umoles of BAIBA in his urine daily before any H3-thymidine injection. This is distinctly above the usual normal levels of BAIBA excretion (16) . The greater amounts of H3-BAIBA excreted by Patient W.S. compared with D.S. I and II may be related to his greater endogenous BAIBA output.
The absence of detectable amounts of nonvolatile tritiated compounds in stools suggests that the labeled gastrointestinal cells, which were subsequently sloughed and degraded in the intestinal lumen, liberated tritiated compounds which were reabsorbed. Since there were no significant perturbations in the turnover of body water, the amount of the labeled materials degraded, reabsorbed, and converted to tritiated water was too small to be detected after dilution in total body water. Unpublished studies (22) have shown that H3-labeled thymidine is absorbed after oral administration in animals and results in labeled cells with the greatest intensity in the gastrointestinal mucosa. Wilson and Wilson (23) have shown that thymidylic acid can be hydrolyzed to thymidine in the gut and subsequently absorbed. From our study and theirs it is reason-
